## **PROGRESSION FROM CUTANEOUS TO SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC LITERATURE REVIEW**

Barinder Singh<sup>1</sup>, Navdeep Kaur<sup>2</sup>, Sumeet Attri<sup>2</sup>, Gagandeep Kaur<sup>2</sup> <sup>1</sup>Pharmacoevidence, London, UK, <sup>1</sup>Pharmacoevidence, Mohali, India

# -Background

-Objective

-Methodology

- A broad spectrum of dermatological signs are included in cutaneous lupus erythematosus (CLE), which may or may not be linked to the emergence of systemic illness, CLE is more frequent than systemic lupus erythematosus (SLE), cutaneous signs of lupus erythematosus (LE) develop first, and in certain cases, CLE subtypes, they can also exist without systemic disease
- SLE a systemic autoimmune disease involves multisystemic involvement and wide variety of cutaneous pathologies are linked to lupus erythematosus<sup>1</sup>



A systematic search was performed across EMBASE® and MEDLINE® databases to identify relevant English studies published between from 2001 to May 2023 providing CLE to SLE progression rate and risk factors in accordance with Preferred Reporting







- Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, Cochrane Handbook and National Institute for Health and Care Excellence standard approach for conducting reviews. The prespecified eligibility criteria is presented in Figure 1
- Two independent reviewers reviewed each study, and a third reviewer resolved disagreements. The analysis was performed using Stata-17 software



- The sample size ranged from 35 to 20,878 (seven studies with <30 patients were excluded)
- The rate of CLE to SLE progression ranged from 4.3% to 57.1% among the included 21 studies.
- Studies varied in terms of geography (Figure 3), design (Figure 4), sample size (Figure 5) and diagnostic criteria (Figure 6)



**Figure 5: Sample size distribution across the included studies** 

Figure 6: Diagnostic criteria across the included studies

A meta-analysis of included studies revealed an estimated 15% rate of CLE to SLE progression (Figure 7)

Study Name	ES (95% CI)	Weight (%
Fredeau 2023	0.18 (0.13, 0.25)	4.91
Yang 2022	0.08 (0.06, 0.11)	5.34
Black 2021	0.11 (0.06, 0.19)	4.84
Chanprapaph 2021	0.10 (0.04, 0.22)	4.33
Baek 2020	0.04 (0.03, 0.06)	5.45
Walocko 2020	0.17 (0.10, 0.28)	4.31
Walocko 2019	0.15 (0.08, 0.26)	4.23
Drenkard 2019	0.05 (0.03, 0.09)	5.33
Petersen 2018	0.12 (0.10, 0.14)	5.46
Hall 2017	0.23 (0.22, 0.23)	5.49
Rees 2015	0.14 (0.12, 0.17)	5.41
Wieczorek 2014	0.17 (0.10, 0.27)	4.43
Wieczorek 2012	0.15 (0.09, 0.24)	4.58
Al-Saif 2012	0.11 (0.05, 0.21)	4.49
Gronhagen 2011	0.13 (0.11, 0.15)	5.40
Insawang 2010	0.21 (0.15, 0.29)	4.71
Durosaro 2009	0.12 (0.08, 0.18)	5.04
Murphy 2019	0.08 (0.04, 0.16)	4.88
Puaratanaarunkon 2022	0.29 (0.20, 0.41)	3.87
Wolff 2020	• 0.57 (0.41, 0.72)	2.86
Walker 2023	0.15 (0.09, 0.24)	4.63
Overall (l <sup>2</sup> = 97.52%, p = 0.00)	0.15 (0.11, 0.19)	100.00
	5	1
a. Complete interval, ES. Effect Size		

Figure 7: Forest plot for rate of CLE to SLE progression

The risk factors for progression were reported in 16 studies. The most common factors associated with SLE development were positive antinuclear antibody (ANA), female gender, earlier age onset, hematologic abnormalities, joint involvement, lupus erythematosus specific skin lesions, presence of immunologic disorders, mucocutaneous criteria, the total number of

### -References

- 2013. Cutaneous lupus erythematosus: diagnosis and treatment. Best practice & research Clinical rheumatology, 27(3) pp.391-404
- Fredeau, L., et. al, 2023. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. Journal of the American Academy of Dermatology, 88(3), pp.551-559
- Walker, A.M., et al, 2023. Decreased progression to systemic lupus erythematosus in patients with cutaneous lupus erythematosus under 13. European League Against Rheumatism/American College of Rheumatology criteria. Journal of the American Academy of Dermatology, 88(1), pp.187-190
- Chanprapaph, K., et al, 2021. Dermatologic manifestations, histologic features and disease progression among cutaneous lupus erythematosus subtypes: a prospective observational study in Asians. Dermatology and therapy, 11, pp.131-147
- Baek, Y.S., et al. 2020. Cutaneous lupus ervthematosus and its association with systemic lupus ervthematosus: A nationwide population-based cohort study in Korea. The Journal of Dermatology, 47(2), pp.163-165
- Wieczorek, I.T., et al, 2014. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA dermatology, 150(3), pp.291-296
- Al-Saif, F.M., at al, 2012. Discoid lupus erythematosus in a Saudi population: clinical and histopathological study. Journal of the Saudi Society of Dermatology & Dermatologic Surgery, 16(1), pp.9-12
- Puaratanaarunkon, T., et al, 2022. Efficacy of antimalarial agents to prevent the progression of discoid lupus erythematosus to systemic lupus erythematosus: A retrospective cross-sectional study. Asian Pacific Journal of Allergy and Immunology
- Black, S.M., et al, 2021. Development of systemic lupus in patients with cutaneous lupus using the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Journal of the American Academy of Dermatology, 85(1), pp.200-202
- 10. Gronhagen, C.M., et al, 2011. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. British Journal of Dermatology, 164(6), pp.1335-1341
- Hall, S.A., et al. 2017. 405 Temporal relationship of cutaneous lupus erythematosus and systemic lupus erythematosus: a large retrospective cohort study
- Petersen, M.P., et al, 2018. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus, 27(9), pp.1424-1430
- Rees, F., et al. 2015, AB0569 How Often Does Cutaneous Lupus Evolve Into Systemic Lupus? a Uk Cohort Stud
- Yang, J.X., et al, 2022, September. Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors. In ARTHRITIS & RHEUMATOLOGY (Vol. 74, pp. 666-667). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY
- Walocko, F., et al, B.F., 2020. Worsening skin damage in patients with cutaneous lupus erythematosus may predict development o systemic lupus erythematosus. Journal of the American Academy of Dermatology, 84(2), pp.538-540
- Wieczorek, I.T., et al. 2012. May, Progression from cutaneous to systemic lupus erythematosus by ACR criteria usually occurs with mild disease and few systemic symptoms. In Journal of Investigative Dermatology (Vol. 132, pp. S45-S45). 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA: NATURE PUBLISHING GROUP
- Insawang, M., et al, 2010. Discoid lupus erythematosus: description of 130 cases and review of their natural history and clinical course. Clin Immunol Immunopathol Res, 2(1), pp.1-8
- Durosaro, O., et al, 2009. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Archives of dermatology, 145(3), pp.249-253
- Wolff, R., et al, 2020, September. Progression to systemic lupus erythematosus: do patients with subacute lupus erythematosus meet American College of Rheumatologists and Systemic Lupus International Collaborating Clinics diagnostic criteria?. In BRITISH JOURNAL OF DERMATOLOGY (Vol. 183, pp. 49-49). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY
- Walocko, F., et al, 2019. 559 Higher skin disease scores distinguish patients who progress from cutaneous lupus erythematosus to systemic lupus erythematosus. Journal of Investigative Dermatology, 139(5), p.S96
- Drenkard, C., et al, 2019. Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the southeasterr Georgia lupus registry. Arthritis care & research, 71(1), pp.95-103

## **–**Disclosure

The authors would like to thank Gunjan Bisht for her valuable contribution in making this poster a success. The authors conducted this research independently, without any external collaboration

#### ACR criteria, SLICC immunologic criteria and total criteria and generalized discoid lupus erythematosus (DLE)



#### Conclusion

- This study provides a broader range and meta-analyzed estimates for progression of CLE to SLE
- A considerable proportion of CLE patients move to SLE, and this study advocates the need for continuous monitoring of CLE patients
- This study also highlights the need for further research to understand the impact of transition from CLE on SLE trial outcomes
- Large-multicenter studies are needed better to understand CLE to SLE transition rate and risk factors



